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Abstract
Background: Primary Sjögren’s syndrome is the second most common rheumatological disorder after rheumatoid
arthritis. It typically presents as xerophthalmia and xerostomia in postmenopausal women. Involvement of the
central nervous system has been recognized, although its pathogenesis and characteristics are poorly understood.
Central nervous system complications are a diagnostic challenge and emphasize the need for systematic screening
of patients with new peripheral and central neurological symptoms.
Case report: We report a case of a 58-year-old Swiss woman presenting with rapidly progressive sensorimotor
distal polyneuropathy together with new-onset generalized seizures. Initial magnetic resonance imaging (MRI) of
the brain performed after the first seizure showed multiple, bihemispheric, confluent white matter hyperintensities
with contrast enhancement. Follow-up imaging 3 days after the initial magnetic resonance imaging demonstrated
a fulminant disease progression associated with the serious clinical deterioration of the patient. In light of the
results of a minor salivary gland biopsy, autoantibody testing, nerve conduction studies, and cranial magnetic
resonance imaging, primary Sjögren’s syndrome with cryoglobulinemia type II was diagnosed. Response to
plasmapheresis and subsequent administration of cyclophosphamide was favorable.
Conclusion: Even though exocrinopathy is the hallmark of Sjögren’s syndrome, systemic symptoms are observed in
one-third of patients. There is an urgent need to better characterize the mechanisms underlying different disease
phenotypes and to perform randomized controlled trials in order to provide tailored and evidence-based treatment
for primary Sjögren’s syndrome.
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Introduction
Primary Sjögren’s syndrome (pSS) is the second most
common rheumatological disorder after rheumatoid arth-
ritis, affecting around 0.5% of the general population [1].
Females are much more often affected by Sjögren’s syn-
drome (SS) than males (9:1 ratio), and onset usually oc-
curs in the fourth or fifth decade of life [2]. SS typically
presents as xerophthalmia and xerostomia in postmeno-
pausal women. Extraglandular manifestations occur in
over 30% of cases, mainly affecting the joints, skin, lungs,
and peripheral nervous system [3, 4].
The American College of Rheumatology (ACR) en-
dorsed the 2012 classification criteria for pSS [5]. These
criteria consist of three items: ocular staining score
(OSS) ≥ 3, positive autoantibodies, and minor salivary
gland biopsy focus score ≥ 1. Patients meeting two of
these criteria are classified as having pSS. In 2016, the
ACR and the European League Against Rheumatism
(EULAR) proposed new classification criteria [6]. They
adopted five objective items with different weights, giv-
ing a higher weight of 3 points each to positive autoanti-
body and positive biopsy results (focus score ≥ 1). OSS ≥
5 (or van Bijsterveld score ≥ 4), Schirmer test ≤ 5 mm/5
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min, and unstimulated salivary flow rate ≤ 0.1 ml/min
each score 1 point. A patient with a total score ≥ 4 is
deemed to have pSS [6]. Involvement of the central ner-
vous system (CNS) has been recognized, although its
pathogenesis and characteristics are varied and poorly
understood [4, 7].
The first published description of CNS involvement
with focal or diffuse symptoms was the series of eight pa-
tients described in 1982 by Alexander et al., who sug-
gested a direct etiopathogenetic role of the anti-Ro
(anti-SSA) antibodies [8]. Because severe neuropsychiatric
syndromes may occur even with the seronegative forms of
pSS, we emphasize the importance for clinicians of being
familiar with the extraglandular manifestations of this syn-
drome [9]. Furthermore, CNS involvement may precede
clinical diagnosis by many years and may lead to an
underestimation of other neurological and/or systemic
diseases [10]. The aim of this case report is to describe the
CNS signs and symptoms in a patient with severe sym-
metric axonal sensorimotor polyneuropathy and rapidly
evolving disseminated cerebral lesions in the presence of
type II cryoglobulins as the predominant finding of pSS.
Case presentation
A 58-year-old Swiss woman presented to our hospital with
a history of ascending numbness in both legs evolving over
the preceding 12months. Three weeks before initial evalu-
ation, she had developed rapid, painless worsening of her
symptoms. Her main complaints were motor weakness and
loss of fine motor skills. Sicca syndrome and Raynaud’s
phenomenon had been present for more than 10 years. The
patient denied having joint pain. Clinical examination re-
vealed distally accentuated, symmetric, flaccid tetraparesis
with areflexia accompanied by hypesthesia up to the knees
and elbows for all sensory qualities. After administration of
intravenous methylprednisolone for suspected inflammatory
polyneuropathy, the patient had her first generalized
tonic-clonic seizure. Despite the administration of levetirac-
etam, another two generalized seizures occurred 24 h later,
after which the patient showed psychomotor slowing,
right-sided hemianopia, and central paresis of the right arm.
The initial electroencephalogram (EEG) after the first
seizure showed slowing of both occipital lobes with tem-
poral acceleration. This finding was more pronounced
on the left side and over the right hemisphere. Electro-
physiological studies revealed a severe axonal sensori-
motor proximal symmetric polyneuropathy with sensory
proximal symmetric accelerated defiance.
Laboratory testing demonstrated rheumatoid factor, an
antinuclear antibody titer of > 1:1280, and antibodies to
SSA/Ro and SSB/La together with hypocomplemente-
mia. Type II cryoglobulins were detectable (cryocrit of
5.4%). Antibodies against double-stranded DNA (deoxy-
ribonucleic acid) were absent. Saxon and Schirmer tests
confirmed severely decreased tear and saliva production.
Biopsy (Fig. 1) of labial minor salivary glands showed
periductal lymphocytic infiltration with a focus score > 1.
On the basis of the positive anti-SSA as well as the saliv-
ary gland biopsy having a focus score > 1 and a Schirmer
test < 5 mm in 5min, the 2017 ACR-EULAR classifica-
tion criteria for pSS were formally fulfilled. Because
there was prominent hypergammaglobulinemia with
markedly elevated light chains, a bone marrow biopsy
was performed, which showed < 10% plasma cells. Flow
cytometry demonstrated expansion of clonal plasma
cells with restricted kappa light chains.
Primary lumbar puncture showed hypergammaglobuli-
nemia with markedly increased light chains. Repeat
Fig. 1 a and b Histology of minor salivary glands. a The histology of minor salivary glands of the lips (H&E staining) revealed diffuse, predominantly
lymphocytic inflammatory infiltrates with formation of lymphocytic foci. b Magnification of one lymphocytic focus
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lumbar punctures during the disease course confirmed
monoclonal gammopathy of undetermined significance
(MGUS) of the immunoglobulin M kappa type.
Initial magnetic resonance imaging (MRI) of the brain
performed after the first seizure showed multiple, bihe-
mispheric, confluent white matter hyperintensities
(WMHs) with contrast enhancement (Fig. 2). The par-
otid gland on both sides and the left submandibular
gland were diffusely enlarged with multiple small cystic
areas and tiny contrast-enhancing nodules (Fig. 2). MRI
was performed 3 days after the first imaging because of
rapid clinical worsening, which demonstrated a fulmin-
ant disease progression (Fig. 3). Consequently, a biopsy
of one of the enhancing lesions in the right frontal lobe
was done. The right frontal dura and slightly thickened
right pia mater were also biopsied and sent for patho-
logical and microbiological testing. The histopathological
results were noncontributory and did not suggest a spe-
cific pattern or definitive diagnosis. The possibility of
microglial activation was discussed. There was no evi-
dence of CNS vasculitis; infection with cytomegalovirus,
herpes simplex virus, JC virus (human polyomavirus 2,
formerly John Cunningham virus), or Toxoplasma gon-
dii; or lymphoma infiltrates.
pSS was suspected in light of the patient’s sicca syn-
drome and results of laboratory testing. The labial minor
salivary gland biopsy showed no evidence of another
underlying rheumatological disorder such as systemic
lupus erythematosus. The fulminant worsening of symp-
toms led us to consider an additional lymphoma in the
course of long-standing SS as a differential diagnosis.
However, progression of the CNS lesions under adminis-
tration of steroids as well as the results of the bone mar-
row biopsy argued against this diagnosis. No evidence
for an immunoglobulin G4 (IgG4)-related disease was
found in the biopsy of the salivary glands, and results of
serological testing for hepatitis C were negative. Results
of the bone marrow biopsy and flow cytometry were
interpreted as MGUS.
After the patient had her third seizure, five sessions of
plasma exchange were conducted over 8 days. After the
second generalized seizure and until plasmapheresis, the
patient showed reduced vigilance and psychomotor
slowing. Thereafter, cyclophosphamide was administered
monthly, along with oral steroids. Plasmapheresis led to
a rapid improvement of the patient’s condition. After the
seventh cycle of cyclophosphamide therapy, the patient
was able to walk unaided for up to 1 h and carry out
everyday activities independently. Steroids were grad-
ually tapered. MRI performed after the second cycle of
cyclophosphamide demonstrated complete resolution of
the contrast-enhancing WMHs (Fig. 4). Six months after
initial presentation, cryoglobulins were no longer detect-
able. Treatment was changed to rituximab given every 6
months. Furthermore, intermittent depressive mood led
to a switch of the antiepileptic therapy from levetirace-
tam to lamotrigine after 6 weeks. The patient is still tak-
ing lamotrigine and is seizure-free. Under therapy with
lamotrigine, the patient had normal EEGs with normal
basic activity and no typical epilepsy signals.
The patient recovered quickly and was able to resume
everyday life within 3 months after leaving the hospital.
The patient is currently doing well with no signs of re-
lapse 1.5 years after initial presentation and has returned
to work.
Discussion
In 1933, the Swedish ophthalmologist Henrik Sjögren
first described the clinical and histological features of
“keratoconjunctivitis sicca” [3]. pSS is distinguished from
a secondary form that occurs in the presence of another
underlying systemic autoimmune disorder, such as
Fig. 2 a–c Initial magnetic resonance imaging (MRI) of the brain. The initial MRI scan showed multiple disseminated, bihemispheric, supratentorial
cortical, and subcortical hyperintense white matter lesions in the axial T2-weighted (3 mm) images, especially in the frontal, parieto-occipital, and
occipitotemporal lobes (a). The white matter hyperintensities revealed contrast enhancement with a diffuse, fine granular pattern (b; axial T1-weighted
image after contrast application, 3mm). The parotid glands were diffusely enlarged on both sides with multiple small cystic areas and tiny contrast-
enhancing nodules (c; coronal T1-weighted MPR after contrast application, 1mm)
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systemic lupus erythematosus. The classical patient is a
postmenopausal woman presenting with ocular and oral
dryness. Fatigue and joint pain are also common, with
involvement of the skin, the lungs, and the nervous sys-
tem being less frequent [3]. The frequency of the neuro-
logical manifestations of pSS is difficult to assess
because of the lack of studies in a broad population of
patients, but it is estimated to be 20% [4, 7]. Peripheral
nervous system impairment is the most common neuro-
logical finding. CNS involvement seems less frequent,
and the reported manifestations are varied (see Table 1).
A retrospective study of 82 patients with pSS on a neur-
ology and internal medicine ward found that neurological
complications were the first symptoms in 81% of patients
[7]. The leading presentation is sensory neuropathy, with
painful small-fiber neuropathy and sensory ataxic neur-
opathy being the most common phenotypes [4, 7, 11–13].
The absence of uniform definitions and the changing clas-
sification criteria as well as referral bias might account for
the wide range of the estimates of prevalence and the het-
erogeneous manifestations of CNS involvement [7, 11].
Focal or multiple cerebral T2 hyperintensities, transverse
myelitis, and optic neuritis mimicking multiple sclerosis
have been described [4, 7, 11], but they are not specific for
pSS. Furthermore, an association with neuromyelitis
optica spectrum disorders has been observed [4].
Fig. 3 a and b Follow-up magnetic resonance imaging (MRI) of the brain. Follow-up MRI of the brain 3 days after the first scan demonstrated a
significant increase in size and extension of the now-confluent white matter lesions on the axial 3-mm fluid-attenuated inversion recovery image
(a), especially notable bilaterally in the frontal and parietal lobes with stipple contrast enhancement with a “miliar” distribution pattern (b; axial T1-
weighted image after contrast application, 3 mm)
Fig. 4 a and b Final magnetic resonance imaging (MRI) of the brain. Follow-up MRI performed 5 months after symptom onset demonstrated
complete regression of the previously documented confluent white matter lesions on the axial T2-weighted (3 mm) image (a) and the contrast
enhancement in the T1-weighted (3mm) image after contrast application (b). At the site of the earlier biopsy, a small liquor isointense parenchymal
defect with a T2-weighted hypointense hemosiderin rim and residual contrast enhancement of the biopsy cavity was seen in the right frontal lobe
(a; arrow)
Ging et al. Journal of Medical Case Reports          (2019) 13:165 Page 4 of 7
Different pathogenetic mechanisms could explain the
complexity of nervous system involvement and the di-
verse clinical presentations. Vasculitis of the vasa ner-
vorum is considered to play a key role in mononeuritis
multiplex, whereas T-cell infiltration in the dorsal root
ganglia has been described in sensory ataxic neuropathy.
Autoantibodies and immune-complex deposition have
also been proposed as an important disease mechanism
[4, 7, 11–14].
As with our patient, clinical characterization is mostly
based on existing neurological syndromes. Imaging
characterization [15–17] or histological characterization
is still insufficient to explain the pathophysiology of pSS.
For all patients with pSS who have clinical signs of
CNS involvement, and in those with autoimmune dis-
eases more generally, neuroimaging for diagnosis and
follow-up should follow a standardized protocol. The
role of brain MRI in the assessment of CNS involvement
in pSS has not yet been fully defined. Diffuse, small, and
punctate WMHs represent a frequent but nonspecific
finding, and their prevalence increases with age, dia-
betes, atherosclerosis, and hypertension [18]. Multiple
WMHs have been detected in up to 80% of patients with
pSS and focal progressive neurological dysfunctions and
in 50% of patients with a diffuse pattern [10, 19]. These
abnormalities have been reported more frequently in
asymptomatic patients with pSS than in age- and
sex-matched healthy subjects [19–21]. In recent years,
specific metabolic tissue markers found by magnetic res-
onance spectroscopy (MRS) in contrast to the presence
of structural damage were described [22]. MRS provides
functional information about the brain region in which
metabolic ratios are measured and has been used fre-
quently in other neuroimmunological conditions, such
as neuropsychiatric systemic lupus erythematosus [23].
The somewhat nonspecific and diffuse neurological
symptoms are likely to be related to an early subtle and
functional impairment of the CNS due to supposed
endotheliitis. Effectively, N-acetylaspartate (NAA) levels
and the NAA/Cr ratio decrease in subcortical frontal
and basal ganglia white matter detected with MRS and
are known to be related to impairment of microvascula-
ture [22]. In our opinion, MRS might detect a potential
early biomarker of CNS involvement in pSS, is less ex-
pensive and less invasive than brain biopsy, and could
avoid performing a brain biopsy that might be inconclu-
sive, as in our patient. Further studies in a larger cohort
of patients with pSS and CNS involvement are needed
to identify patterns of brain involvement in pSS more
clearly. MRI with MRS might represent an effective
method for the early diagnosis of CNS involvement, par-
ticularly when neurological symptoms precede systemic
involvement. Persistent disability appears to be more fre-
quent in patients with CNS involvement than in those
with peripheral nervous system involvement, suggesting
the need for intensive and early treatment in cases of
CNS involvement [18]. Clinicians should always consider
pSS in patients presenting with polyneuropathy and/or
neurological symptoms that are not typical of other
autoimmune CNS disorders.
Feared complications of long-standing SS are cryo-
globulinemic vasculitis and B-cell lymphoma. Dela-
lande et al. detected mixed cryoglobulins in 36.6% of
their patients with nervous system involvement [7].
Cryoglobulinemia is most often seen in patients with
sensorimotor polyneuropathy and is associated with
severe extraglandular manifestations and an increased
risk of lymphoma [12].
Diagnosis requires serological (presence of SSA/Ro or
SSB/La) or histological (minor salivary gland biopsy) evi-
dence of autoimmunity. Objective testing of ocular and
oral dryness should be performed (such as with Schir-
mer and Saxon tests). Hepatitis C virus and human im-
munodeficiency virus infection, lymphoma, sarcoidosis,
and IgG4-related disease should be excluded [3].
Depending on disease manifestation, treatment ranges
from topical agents to relieve ocular and oral dryness to
administration of systemic immunosuppressive drugs in
patients with organ involvement. Studies are hampered
by differing classification systems and a lack of good
clinical endpoints. Steroids represent the mainstay of
therapy. Intravenous immunoglobulin has been reported
to positively affect disease course in small-fiber and sen-
sory ataxic neuropathy [4, 7, 11–13]. Due to their patho-
genetic role, monoclonal antibodies targeting B-cells
Table 1 Neurological complications of primary Sjögren’s
syndrome
Peripheral nervous system
involvement
Central nervous system involvement
Sensory neuronopathy Focal manifestations (for example, motor/
sensory deficit)
Sensorimotor
polyneuropathy
Aseptic meningoencephalitis
Mononeuritis multiplex Myelopathy
Demyelinating
polyradiculoneuropathy
Headache
Cranial nerve involvement Cognitive disorders
Autonomic neuropathy Mood disorders
Myasthenia gravis Seizure
Pyramidal signs
Brainstem signs
Cerebellar syndrome
Encephalopathy
Spinal cord involvement
Multiple sclerosis–like disease
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(including rituximab and belimumab) are increasingly
used [24]. In life-threatening disease related to cryoglo-
bulinemic vasculitis, plasma exchange followed by cyclo-
phosphamide or rituximab should be considered [24].
With a deeper understanding of disease mechanisms
and the establishment of prognostic markers, more tai-
lored treatment regimens are expected to evolve.
Conclusion
Extraglandular manifestations of pSS comprising arthral-
gia, skin and lung, and peripheral nervous system in-
volvement can be observed in up to one-third of
patients. Involvement of the CNS has also been recog-
nized, although its pathogenesis and characteristics are
varied and poorly understood. This case report under-
lines the diversity of neurological complications of pSS.
The low frequency of neurological symptoms as the first
manifestation of pSS, especially in the event of CNS in-
volvement, could explain why SS is often underdiag-
nosed or diagnosis is delayed. Magnetic resonance
screening for pSS should be systematically performed in
cases of acute or chronic myelopathy, axonal sensori-
motor neuropathy, or clinical suspicion of CNS
involvement.
Cryoglobulinemic vasculitis should be considered if a
rheumatoid factor together with hypocomplementemia
can be detected in a patient with SS. Affected patients
are at increased risk of developing lymphoma as well as
severe systemic complications and should be closely
monitored. Treatment of SS is based on the clinical
symptoms and their severity. Given the rarity of CNS in-
volvement, therapy mostly relies on expert opinion.
Take-home points
Extraglandular manifestations of pSS as well as periph-
eral nervous system involvement are seen in up to
one-third of patients. Involvement of the CNS has also
been recognized, although its pathogenesis and charac-
teristics are varied and poorly understood.
Cryoglobulinemic vasculitis should be considered if a
rheumatoid factor together with hypocomplementemia
can be detected in a patient with SS. Affected patients
are at increased risk of developing lymphoma as well as
severe systemic complications and should be closely
monitored.
Neurological onset often precedes by many years both
the appearance of systemic symptoms and the immuno-
logical diagnosis. Thus, pSS should always be considered
in patients with relatively nonspecific neurological symp-
toms associated with sicca syndrome. MRI and neuro-
psychological assessment are necessary for an early
diagnosis, particularly when neurological symptoms pre-
cede systemic involvement. Because of the great hetero-
geneity of neurological involvement in pSS, neurological
complications should be the subject of large prospective
cohort studies.
Treatment of SS is based on clinical symptoms and
their severity. Given the rarity of CNS involvement, ther-
apy mostly relies on expert opinion.
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